AstraZeneca Bets on Nanotech with Bind Therapeutics Deal

22.04.2013 - AstraZeneca is to pay privately held Bind Therapeutics as much as $200 million to develop a cancer medicine using the U.S. biotech company's nanotechnology drug delivery system...